Chris Reutelingsperger

Chris Reutelingsperger is Professor of Biochemistry of Apoptosis at the Cardiovascular Research Institute (CARIM) of Maastricht University. He is PI of the research theme “Vascular Aspects”. He supervises the research lines addressing molecular and cellular mechanisms of vascular aging, includingatherosclerosis and vascular calcification. His interests focus on cell death programs, phagocytosis, autophagy, annexins, with emphasis on annexins A1 and A5, and vitamin K-dependent proteins. His strategy encompasses establishing collaborations with clinical research and industry. Reutelingsperger discovered annexin A5 and invented the annexin A5-affinity assay to measure apoptosis. He is (co-)inventor of 10 granted patents and CSO of PharmaTarget, a biotech company which he co-founded in 2006. Reutelingsperger studied Biochemistry at the University of Utrecht and received his PhD degree from the Faculty of Medicine at Maastricht University in 1987. He was awarded the 5-years Senior Fellowship of the Royal Dutch Academy of Sciences (KNAW) in 1987. He published over 150 peer-reviewed papers.